Charles Russell Speechlys advises Kreos on growth capital investment in biotech company JenaValve Technologies, Inc.
Charles Russell Speechlys has advised Kreos Capital V (UK) Limited (“Kreos”) on its growth capital investment in JenaValve Technologies, Inc., a biotech company founded to develop next generation transcatheter aortic valve replacement systems for transapical and transfemoral implantation.
By virtue of its anatomically-based locator fixation and dual sealing valve design, the JenaValve Pericardial TAVR System is intended to enable ease of use, reduced risks of paravalvular regurgitation and need for permanent pacing, and durability of patient hemodynamic outcomes.
The Charles Russell Speechlys team was led by Corporate Legal Director Rossana Conti and comprised Banking Partner Daniel Sullivan and Banking Associate Roya Zohrabi. Our team worked in collaboration with Golenbock Eiseman Assor Bell & Peskoe LLP, a US law firm.
This deal further showcases the growing breadth and depth of our Life Sciences practice.